Genmab A/S announced today updated data from cohort B2 of the Phase 1/2 RAINFOLtm-01 trial evaluating rinatabart sesutecan (Rina-S®), an investigational folate receptor alpha (FR?)-targeted, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback